Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 g to 100 g estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 g to 100 g of vitamin D equivalent.

The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 g to 100 g estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 g to 100 g of vitamin D equivalent.

Compositions include an extended release fat-soluble active composition. In certain aspects, the extended release fat-soluble active composition includes an extended release bead multiparticulate comprising a fat-soluble active. In other aspects, the extended release fat-soluble active composition includes an extended release lipid multiparticulate comprising a fat-soluble active.

Compositions include an extended release fat-soluble active composition. In certain aspects, the extended release fat-soluble active composition includes an extended release bead multiparticulate comprising a fat-soluble active. In other aspects, the extended release fat-soluble active composition includes an extended release lipid multiparticulate comprising a fat-soluble active.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or -hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation -hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme -glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.

Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme -glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.